RECOMBINANT EPHB4-HSA FUSION PROTEIN
RECOMBINANT EPHB4-HSA FUSION PROTEIN Uses, Dosage, Side Effects, Food Interaction and all others data.
RECOMBINANT EPHB4-HSA FUSION PROTEIN is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).
| Trade Name | RECOMBINANT EPHB4-HSA FUSION PROTEIN |
| Generic | SEphB4-HSA |
| SEphB4-HSA Other Names | RECOMBINANT EPHB4-HSA FUSION PROTEIN |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here RECOMBINANT EPHB4-HSA FUSION PROTEIN
